文献速递哮喘

支气管热成形术与美泊利单抗在重度哮喘中的疗效比较

Bronchial thermoplasty versus mepolizumab: Comparison of outcomes in a severe asthma clinic.
PubMed 文献 · Respirology · 2020-05-04

12个月时两组在ACQ评分、急性发作率、缓解药物使用、口服激素减量及FEV1改善方面均无显著差异,提示BT疗效与美泊利单抗相当。

要点

  • 12个月时BT与美泊利单抗在ACQ、急性发作率、缓解药物及口服激素减量上无差异。
  • 两组FEV1改善程度相当(BT 150±460 mL vs 美泊利单抗160±290 mL)。
  • 美泊利单抗组12个月停药率25.5%,其中14.9%因不良事件或不依从。

核心结论

  • BT治疗重度哮喘的疗效与美泊利单抗相当。

主要发现

  • 12个月时ACQ评分两组无差异(美泊利单抗1.9±1.3 vs BT 1.7±1.3)。
  • 急性发作率无差异(0.9±1.1 vs 0.9±1.5)。
  • 缓解药物使用减少无差异(-6.3±10.5 vs -5.0±8.8喷/天)。
  • 口服激素减量无差异(-3.3±7.5 vs -5.8±6.7 mg/天)。
  • FEV1改善相当(160±290 vs 150±460 mL)。

关键数值与推荐

  • BT组再入院或延长住院比例为18.2%。
  • 美泊利单抗组12个月停药率25.5%,其中14.9%因不良事件或不依从。

临床怎么用

  • 对于重度哮喘患者,BT与美泊利单抗均可作为治疗选择,疗效相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: BT and interleukin-blocking monoclonal antibodies are both effective therapies for severe asthma, but there have been no direct comparisons between the two treatments. The aim of this study was to compare the efficacy and safety of BT and mepolizumab, in a real-world setting. METHODS: Patients with severe asthma despite optimized inhaler therapy were drawn from a severe asthma clinic in a tertiary hospital. Every patient commencing therapy with BT or mepolizumab was prospectively included in a national registry. At predetermined assessment points over a 12-month period, assessments were made of ACQ, spirometry, oral corticosteroid requiring exacerbations, reliever medication and maintenance oral corticosteroid use. RESULTS: A total of 91 patients with severe asthma participated: mean ACQ score 3.5 ± 1.0, FEV1 51.4 ± 17.7%, maintenance oral steroids 48.3% and 11.5 ± 10.0 inhalations/day reliever therapy. Forty-seven patients received mepolizumab and 44 received BT. Baseline characteristics were similar except significantly higher blood eosinophil count in the mepolizumab group. At 12 months, there were no differences between treatment outcomes for ACQ (1.9 ± 1.3 mepolizumab vs 1.7 ± 1.3 BT), exacerbation rate (0.9 ± 1.1 vs 0.9 ± 1.5), reduction in reliever use (-6.3 ± 10.5 vs -5.0 ± 8.8 puffs/day) or reduction in oral corticosteroids (-3.3 ± 7.5 vs - 5.8 ± 6.7 mg/day). The FEV1 improved equally (160 ± 290 vs 150 ± 460 mL). Readmission or prolonged admission was observed in 18.2% of BT patients, whilst 25.5% of mepolizumab patients had discontinued treatment at 12 months, 14.9% due to an adverse event or non-compliance. CONCLUSION: The results suggest that BT is as efficacious as mepolizumab for the treatment of severe asthma.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Langton D, Sha J, Guo S, et al. Bronchial thermoplasty versus mepolizumab: Comparison of outcomes in a severe asthma clinic. Respirology. 2020. PMID: 32365431. doi:10.1111/resp.13830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。